After An Upbeat J.P. Morgan, Three Biopharmas Look To Kick Off IPOs For 2024

 
• By Andrew McConaghie
  
Generate a summary of this article
Listen to this article
Beta

Gene editing company Metagenomi and two oncology biopharmas will test the IPO waters soon – with hopes this could pave the way for others.

Share price movement
• Source: Shutterstock

2023 was another tough year for biotech initial public offerings, but there are some signs that 2024 could see the market open up again. After a more upbeat mood at the J.P. Morgan conference (JPM) and signs of improving macro-economic stability, the next big test for biotech is a trio of planned flotations. These will come from gene-editing specialist Metagenomi and cancer-focused start-ups ArriVent Biopharma and CG Oncology.

Key Takeaways

  • After two tough years for early-stage biotech, there are signs IPOs and other funding could revive in 2024

All three IPO filings were made ahead of the annual San Francisco investor conference which took place this week, but...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.